Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy.

International Journal of Fertility and Womens Medicine Pub Date : 2007-03-01

Gabriele Urban, Patrizia Vergani, Roberta Tironi, Patrizia Ceruti, Emanuela Vertemati, Francesca Sala, Enrico Pogliani, Elizabeth W Triche, Charles J Lockwood, Michael J Paidas

{"title":"Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy.","authors":"Gabriele Urban, Patrizia Vergani, Roberta Tironi, Patrizia Ceruti, Emanuela Vertemati, Francesca Sala, Enrico Pogliani, Elizabeth W Triche, Charles J Lockwood, Michael J Paidas","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: To determine whether prophylactic low dose aspirin (LDA) alone or in combination with low-molecular-weight-heparin (LMWH) reduces the recurrence of adverse pregnancy outcome (APO).Study design: In this retrospective cohort study, 84 consecutive multiparous patients with a previous history of severe preeclampsia (sPE) and intrauterine growth restriction (IUGR) (<10%ile) were assigned to receive no treatment, LDA alone, or LDA and LMWH. Odds ratios were calculated from logistic regression models.Results: Combined LDA and LMWH significantly reduced the risk of developing IUGR in the index pregnancy (OR = 0.16, 95% CI: 0.03-0.98). Among women with antecedent sPE (n=52), combined treatment reduced APO in the index pregnancy (OR = 0.08, CI: 0.01-0.96), IUGR (OR = 0.02, CI: <0.01-0.46), and IUGR with sPE (OR = 0.08, CI: 0.01-0.96).Conclusion: Combined treatment with LDA and LMWH is strongly protective against the development of APO in a cohort of women with antecedent APO.","PeriodicalId":50324,"journal":{"name":"International Journal of Fertility and Womens Medicine","volume":"52 2-3","pages":"59-67"},"PeriodicalIF":0.0000,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Fertility and Womens Medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To determine whether prophylactic low dose aspirin (LDA) alone or in combination with low-molecular-weight-heparin (LMWH) reduces the recurrence of adverse pregnancy outcome (APO).

Study design: In this retrospective cohort study, 84 consecutive multiparous patients with a previous history of severe preeclampsia (sPE) and intrauterine growth restriction (IUGR) (<10%ile) were assigned to receive no treatment, LDA alone, or LDA and LMWH. Odds ratios were calculated from logistic regression models.

Results: Combined LDA and LMWH significantly reduced the risk of developing IUGR in the index pregnancy (OR = 0.16, 95% CI: 0.03-0.98). Among women with antecedent sPE (n=52), combined treatment reduced APO in the index pregnancy (OR = 0.08, CI: 0.01-0.96), IUGR (OR = 0.02, CI: <0.01-0.46), and IUGR with sPE (OR = 0.08, CI: 0.01-0.96).

Conclusion: Combined treatment with LDA and LMWH is strongly protective against the development of APO in a cohort of women with antecedent APO.

本刊更多论文

抗血栓预防在多胎妇女先兆子痫或宫内生长迟缓的前妊娠。

目的:探讨预防性低剂量阿司匹林(LDA)单用或联用低分子肝素(LMWH)是否能减少不良妊娠结局(APO)的复发。研究设计:在这项回顾性队列研究中，84例连续多次分娩且既往有严重子痫前期(sPE)和宫内生长限制(IUGR)病史的患者(结果:LDA和低分子肝素联合应用可显著降低指数妊娠发生IUGR的风险(OR = 0.16, 95% CI: 0.03-0.98)。在既往有sPE的女性(n=52)中，联合治疗降低了指数妊娠APO (OR = 0.08, CI: 0.01-0.96)和IUGR (OR = 0.02, CI:结论:LDA和低分子肝素联合治疗对既往有APO的女性APO的发展有很强的保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Fertility and Womens Medicine

自引率

0.00%

发文量